Financial Conflicts of Interest in Clinical Trials

Julie D. Gottlieb ()
Additional contact information
Julie D. Gottlieb: Johns Hopkins University School of Medicine

Chapter 28 in Principles and Practice of Clinical Trials, 2022, pp 541-557 from Springer

Abstract: Abstract Because clinical trials are the gold standard for evaluating the safety and efficacy of drugs and medical devices, they should be conducted as safely and objectively as possible. Objectivity can be affected by study design and conduct, but additional risks to objectivity – and possible risks to safety – may arise from financial conflicts of interest (FCOIs). The explosion in recent decades of financial relationships between medical researchers and the pharmaceutical and medical device industry means it is very likely that at least some members of most clinical trial study teams will have a financial tie with the sponsor or manufacturer of the study drug or device. Payments of various types are ubiquitous. The data on payments to physicians published by the Center for Medicare and Medicaid Services (CMS) since 2014 offers evidence that approximately half of all physicians have financial ties with industry (Tringale et al. 2017). Social science studies have demonstrated that financial interests can give rise to conscious or unconscious bias in favor of the product being tested or its manufacturer. In addition, when institutions that are clinical trial sites have financial interests related to a clinical trial, the institutional conflicts of interest (institutional COIs) can create risks to the objectivity or safety of the study. So close attention to conflict of interest issues is essential for protecting the integrity of clinical trials. This chapter will examine the nature of the risks at issue, key regulations and standards for addressing FCOIs in research, key elements of FCOI policies, and approaches to evaluating and addressing FCOIs.

Keywords: COI committee; Data safety monitoring board; Disclosures; Financial conflicts of interest; Institutional conflicts of interest; Management plan; Technology licensing (search for similar items in EconPapers)
Date: 2022
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-3-319-52636-2_275

Ordering information: This item can be ordered from
http://www.springer.com/9783319526362

DOI: 10.1007/978-3-319-52636-2_275

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().